Genentech Reports Positive Phase III Results for Gazyva in Primary Membranous Nephropathy

Genentech, a member of the Roche Group, announced positive topline results from the Phase III GEMMA trial evaluating Gazyva (obinutuzumab) in combination with glucocorticoids for the treatment of primary membranous nephropathy (PMN). The trial met its primary endpoint of complete or partial renal response at week 24 compared to placebo plus glucocorticoids. Gazyva is already approved for certain types of blood cancers; this data supports its potential expansion into kidney disease. The GEMMA study enrolled 330 patients across multiple countries. Gazyva demonstrated a statistically significant improvement in renal response rates without increasing serious adverse events. Genentech plans to submit the data to global health authorities in the coming months for potential approval in PMN. Shares of Roche Holdings (ROG.VX) were up 1.2% in early trading.